ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target